https://www.medscape.com/viewarticle/891540
The latest quarterly watch list from the US Food and Drug Administration (FDA) includes 15 drugs or drug classes for which there is new safety information or possible signs of serious risk.
The watch list, updated January 12 on the FDA website, is created from the FDA Adverse Event Reporting System (FAERS).
Placement on this list does not mean the FDA has found that a drug is associated with the listed risk, only that the FDA has identified a potential safety problem. If a further review concludes that the drug is associated with the risk or causes a problem, the FDA has many options for further action, including requiring changes to labeling, restricting use of the drug, or, in rare cases, pulling a product from the market. Follow us for more details salbreux-pesage .
The current list, which is from the third quarter of 2017 (July-September), includes 11 antibiotics for which the FDA saw signs of potential risk for hypoglycemic coma and nine antidepressants the FDA flagged because of a potential risk for DRESS (drug reaction with eosinophilia and systemic symptoms).
For two drugs on the list, potential risk has resulted in changes to labels. Ibrutinib capsules (Imbruvica, Pharmacyclis Inc) were listed because of signs of potential risk for ventricular arrhythmia. The Warnings and Precautions section of the labeling for the drug has since been updated to include ventricular arrhythmia. For selexipag tablets (Uptravi, Actelion Phamaceuticals Ltd), the Adverse Reactions: Postmarketing Experience section of the labeling was updated to include hypotension. songsforromance provides you more details.
For all but one of the other drugs listed, the FDA is evaluating whether regulatory action is needed. The exception is rivaroxaban tablets (Xarelto, Janssen Pharmaceuticals), for which the FDA has determined there is no need for action at this time.
Table.
| Active Ingredient (Trade Name) or Product Class | Potential Signal of a Serious Risk/New Safety Information | Additional Information (as of January 12, 2018) |
|---|---|---|
| Tocilizumab injection (Actemra), for intravenous or subcutaneous use. | Pancreatitis, hepatotoxicity | FDA is evaluating the need for regulatory action. |
|
Serious skin reactions | FDA is evaluating the need for regulatory action. |
|
DRESS (drug reaction with eosinophilia and systemic symptoms) | FDA is evaluating the need for regulatory action. |
|
Hypoglycemic coma | FDA is evaluating the need for regulatory action. |
|
Rebound pruritis | FDA is evaluating the need for regulatory action. |
| Pseudoephedrine | Acute generalized exanthematous pustulosis | FDA is evaluating the need for regulatory action. |
| Ibrutinib capsules (Imbruvica) | Hepatotoxicity and ventricular arrhythmia | Regarding hepatotoxicity, FDA is evaluating the need for regulatory action. Regarding ventricular arrhythmia, the Warnings and Precautions section of the labeling was updated to include ventricular arrhythmia. |
|
Drug interaction with nitrous oxide, potentiated effect of methotrexate on folate metabolism, resulting in increased toxicity (severe myelosuppression, stomatitis, and neurotoxicity) | FDA is evaluating the need for regulatory action. |
| Nafcillin injection, USP, for intravenous use | Acute renal failure | FDA is evaluating the need for regulatory action. |
| Obeticholic acid tablets (Ocaliva), for oral use | Liver injury | FDA is evaluating the need for regulatory action. |
|
Wrong dosing frequency errors (once-daily administration instead of intended once-weekly administration) | FDA is evaluating the need for regulatory action. |
| Eculizumab injection (Soliris), for intravenous use | Nongroupable meningitis infections and Neisseria (other than N. meningitides) infections | FDA is evaluating the need for regulatory action. |
| Selexipag tablets (Uptravi) | Hypotension | The Adverse Reactions: Postmarketing Experience section of the labeling was updated to include hypotension. |
| Cariprazine capsules (Vraylar) | Stevens-Johnson syndrome | FDA is evaluating the need for regulatory action. |
| Rivaroxaban tablets (Xarelto) | Liver injury | FDA decided on the basis of available information that no action is necessary at this time. |
| Source: FDA | ||
More information about FAERS and its quarterly watch lists is available on the FDA website.
Filed under: General Problems
Every antidepressant drug I have tried in the past made me worse. Yet, they were handed out like candy. No one ever mentioned that suddenly stopping them is dangerous, as I found out after nearly blacking out. The only medications that worked to the degree to be where I could live my true potential are now both corrupted, unrecognizable or not prescribed. I,m not an idiot, I know this isn’t about HEALTH, it’s about suffering and death. Who is dangerously Mentally Il?
I get it now! Anything that the government can control is good no matter how much harm it causes but herbs, supplements, prescribed pain medication, marijuana and kratom are bad. Their thought processes are as clear as a mud bog!!